Search results for novartis
Novartis achieved record results for the total Group in 2007, with net sales rising 8% (+3% in local currencies) and net income advancing 66% to USD
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
European health authorities have supported changes proposed by Novartis to prescribing information for Galvus® (vildagliptin), opening the way for th
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Novartis (NVS) will cut 2,500 jobs worldwide by 2010 in an attempt to save $1.6 billion, the drugmaker said Thursday, becoming the latest major pharmaceutical company to announce layoffs. The company
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Vasella's compensation in 2007 fell by about 20% from the previous year, to 17 million Swiss francs, according to Novartis's annual report. How come? Novartis failed to meet some of its financial a
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Novartis announced the opening of a new research institute in Siena with a nonprofit mission to exclusively focus on the development of vaccines for diseases of the developing world. The Novartis Vac
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Novartis's chief Dan Vasella took a moment today to explain to shareholders why he should remain as both chairman and CEO. At the company's annual meeting, Vasella argued that splitting the roles b
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Shares of Swiss drug maker Novartis AG fell Friday after an HSBC analyst downgraded the stock on concerns that generic competition will stunt Novartis' profit and revenue growth. HSBC analyst Kevin
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Women may reduce the risk of their breast cancer returning by starting treatment with Femara® (letrozole) anywhere from one to seven years after finishing tamoxifen therapy, according to a new analys
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Rasilez® (aliskiren), the first-in-class direct renin inhibitor, has shown clinically meaningful reductions in left ventricular hypertrophy, a proven predictor of heart disease, that are comparable t
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Novartis has reached an agreement with Nestlé S.A. providing the right to acquire majority ownership of Alcon Inc. (NYSE: ACL) in two steps and add the world leader in eye care to its diversified por
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
